New mechanisms: From lactate to lactylation to rescue heart failure.

Titin heart failure lactylation sarcomeric structure and function α-MHC

Journal

Bioscience trends
ISSN: 1881-7823
Titre abrégé: Biosci Trends
Pays: Japan
ID NLM: 101502754

Informations de publication

Date de publication:
19 Mar 2024
Historique:
pubmed: 8 2 2024
medline: 8 2 2024
entrez: 7 2 2024
Statut: ppublish

Résumé

Lactylation of α-myosin heavy chain (α-MHC) has recently been reported to preserve sarcomeric structure and function and attenuate the development of heart failure. Specifically, lactylation enhanced the interaction of α-MHC with the sarcomeric protein Titin, thereby maintaining normal sarcomeric structure and myocardial contractile function. Furthermore, the administration of lactate or inhibition of lactate efflux potentially treats heart failure by restoring lactylation of α-MHC and the interaction of α-MHC with Titin. This finding highlights the significant role of α-MHC lactylation in myocardial diseases and presents a new therapeutic target for the treatment of heart failure.

Identifiants

DOI: 10.5582/bst.2024.01000 PMID: 38325822
pubmed: 38325822
doi: 10.5582/bst.2024.01000
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105-107

Auteurs

Linfeng Yi (L)

Department of Clinical Laboratory Medicine, Institution of microbiology and infectious diseases, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Clinical Research Center for Myocardial Injury in Hunan Province, Hengyang, Hunan, China.
Institute of Cardiovascular Disease, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hunan Provincial Key Laboratory of Multi-omics And Artificial Intelligence of Cardiovascular Diseases, University of South China, Hengyang, Hunan, China.

Dan Tang (D)

Department of Clinical Laboratory Medicine, Institution of microbiology and infectious diseases, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Clinical Research Center for Myocardial Injury in Hunan Province, Hengyang, Hunan, China.
Institute of Cardiovascular Disease, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hunan Provincial Key Laboratory of Multi-omics And Artificial Intelligence of Cardiovascular Diseases, University of South China, Hengyang, Hunan, China.

Xing Xiang (X)

Department of Clinical Laboratory Medicine, Institution of microbiology and infectious diseases, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Clinical Research Center for Myocardial Injury in Hunan Province, Hengyang, Hunan, China.
Institute of Cardiovascular Disease, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hunan Provincial Key Laboratory of Multi-omics And Artificial Intelligence of Cardiovascular Diseases, University of South China, Hengyang, Hunan, China.

Chungang Xiao (C)

Department of Cardiology, Hunan University of Medicine General Hospital, Huaihua, Hunan, China.

Huifang Tang (H)

Clinical Research Center for Myocardial Injury in Hunan Province, Hengyang, Hunan, China.
Institute of Cardiovascular Disease, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hunan Provincial Key Laboratory of Multi-omics And Artificial Intelligence of Cardiovascular Diseases, University of South China, Hengyang, Hunan, China.
Department of Cardiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Hong Huang (H)

Clinical Research Center for Myocardial Injury in Hunan Province, Hengyang, Hunan, China.
Institute of Cardiovascular Disease, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hunan Provincial Key Laboratory of Multi-omics And Artificial Intelligence of Cardiovascular Diseases, University of South China, Hengyang, Hunan, China.

Classifications MeSH